HC Wainwright Reaffirms “Buy” Rating for Werewolf Therapeutics (NASDAQ:HOWL)

HC Wainwright reiterated their buy rating on shares of Werewolf Therapeutics (NASDAQ:HOWL) in a research note issued to investors on Wednesday,Benzinga reports. HC Wainwright currently has a $15.00 price target on the stock.

Separately, JMP Securities reduced their price objective on Werewolf Therapeutics from $12.00 to $4.00 and set a “market outperform” rating for the company in a research report on Tuesday, January 14th.

Werewolf Therapeutics Trading Down 2.4 %

HOWL opened at $1.23 on Wednesday. The stock has a market cap of $54.81 million, a PE ratio of -0.80 and a beta of 0.37. The company has a quick ratio of 10.10, a current ratio of 10.10 and a debt-to-equity ratio of 0.29. The business has a 50 day moving average of $1.37 and a 200-day moving average of $1.82. Werewolf Therapeutics has a 52 week low of $1.03 and a 52 week high of $6.89.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.03). Werewolf Therapeutics had a negative net margin of 578.80% and a negative return on equity of 58.83%. Equities research analysts predict that Werewolf Therapeutics will post -1.56 earnings per share for the current fiscal year.

Institutional Trading of Werewolf Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of HOWL. Walleye Capital LLC increased its holdings in shares of Werewolf Therapeutics by 10.7% in the 3rd quarter. Walleye Capital LLC now owns 108,968 shares of the company’s stock worth $231,000 after purchasing an additional 10,528 shares in the last quarter. PFM Health Sciences LP increased its holdings in shares of Werewolf Therapeutics by 4.9% in the 3rd quarter. PFM Health Sciences LP now owns 3,398,747 shares of the company’s stock worth $7,205,000 after purchasing an additional 157,673 shares in the last quarter. State Street Corp increased its holdings in shares of Werewolf Therapeutics by 12.4% in the 3rd quarter. State Street Corp now owns 476,439 shares of the company’s stock worth $1,010,000 after purchasing an additional 52,528 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of Werewolf Therapeutics in the 3rd quarter worth $45,000. Finally, Barclays PLC increased its holdings in shares of Werewolf Therapeutics by 130.1% in the 3rd quarter. Barclays PLC now owns 54,810 shares of the company’s stock worth $116,000 after purchasing an additional 30,990 shares in the last quarter. Institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.